| Dry Eye Syndromes
Tyrvaya vs Xiidra
Side-by-side clinical, coverage, and cost comparison for dry eye syndromes.Deep comparison between: Tyrvaya vs Xiidra with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXiidra has a higher rate of injection site reactions vs Tyrvaya based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xiidra but not Tyrvaya, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tyrvaya
Xiidra
At A Glance
Nasal spray
Twice daily
Nicotinic acetylcholine receptor agonist
Ophthalmic
Twice daily
LFA-1 antagonist
Indications
- Dry Eye Syndromes
- Dry Eye Syndromes
Dosing
Dry Eye Syndromes One spray in each nostril twice daily, approximately 12 hours apart; prime with 7 actuations before initial use and re-prime with 1 actuation if not used for more than 5 days.
Dry Eye Syndromes Instill one drop twice daily (approximately 12 hours apart) into each eye using a single-use container; remove contact lenses prior to administration and reinsert 15 minutes after.
Contraindications
—
- Known hypersensitivity to lifitegrast or any other ingredient in the formulation
Adverse Reactions
Most common (>=5%) sneezing (82%), cough (16%), throat irritation (13%), instillation-site (nose) irritation (8%)
Most common (>=5%) Instillation-site irritation, dysgeusia, reduced visual acuity
Common (1%-5%) Blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus, sinusitis
Postmarketing Hypersensitivity reactions including anaphylactic reaction, bronchospasm, respiratory distress, pharyngeal edema, swollen tongue, urticaria, allergic conjunctivitis, dyspnea, angioedema, allergic dermatitis, eye swelling, rash
Pharmacology
Nicotinic acetylcholine receptor agonist; varenicline binds heteromeric nACh receptor subtypes (alpha4beta2, alpha4alpha6beta2, alpha3beta4, alpha3alpha5beta4) and the alpha7 receptor, activating the trigeminal parasympathetic pathway to increase basal tear film production in dry eye disease.
LFA-1 antagonist; lifitegrast binds to integrin LFA-1 on leukocytes, blocking its interaction with ICAM-1 and inhibiting T-cell adhesion and migration, thereby reducing inflammation in dry eye disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tyrvaya
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Xiidra
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Tyrvaya
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (6/8)
Xiidra
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Tyrvaya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Xiidra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Tyrvaya.
No savings programs available for Xiidra.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TyrvayaView full Tyrvaya profile
XiidraView full Xiidra profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.